Katerina Kotzampassi

Dr. Katerina Kotzampassi

Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2015 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
GSGeorge Stavrou
George Stavrou
GDGeorgia Damoraki
Georgia Damoraki
MGMarianna Georgitsi
Marianna Georgitsi
GBGeorge Basdanis
George Basdanis
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis

7 September 2006 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
EGEvagellos J. Giamarellos‐Bourboulis
Evagellos J. Giamarellos‐Bourboulis
AVAntonios Voudouris
Antonios Voudouris
PKPantelis Kazamias
Pantelis Kazamias
EEEfthimios Eleftheriadis
Efthimios Eleftheriadis

1 January 1996 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
EEE. Eleftheriadis
E. Eleftheriadis
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
KPK. Papanotas
K. Papanotas
NHN. Heliadis
N. Heliadis
KSK. Sarris
K. Sarris

28 January 2012 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
VGVasilis Grosomanidis
Vasilis Grosomanidis
PPPyrros Papakostas
Pyrros Papakostas
SPSofia Penna
Sofia Penna
EEEfthymios Eleftheriadis
Efthymios Eleftheriadis

8 August 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
ATAnna Norrby Teglund
Anna Norrby Teglund
VMVassiliki Mylona
Vassiliki Mylona
ASAthina Savva
Athina Savva
Iraklis TsangarisIraklis Tsangaris
Iraklis Tsangaris
George DimopoulosGeorge Dimopoulos
George Dimopoulos
Introduction: Early risk assessment is the mainstay of management of patients with sepsis. APACHE II is the gold standard prognostic stratification system. A prediction rule that aimed to improve prognostication by APACHE II with the application of serum suPAR (soluble urokinase plasminogen activator receptor) is developed. Methods: A prospective study cohort enrolled 1914 patients with sepsis including 62.2% with sepsis and 37.8% with severe sepsis/septic shock. Serum suPAR was measured in samples drawn after diagnosis by an enzyme-immunoabsorbent assay; in 367 patients sequential measurements were performed. After ROC analysis and multivariate logistic regression analysis a prediction rule for risk was developed. The rule was validated in a double-blind fashion by an independent confirmation cohort of 196 sepsis patients, predominantly severe sepsis/septic shock patients, from Sweden. Results: Serum suPAR remained stable within survivors and non-survivors for 10 days. Regression analysis showed that APACHE II ≥17 and suPAR ≥12 ng/ml were independently associated with unfavorable outcome. Four strata of risk were identified: i) APACHE II <17 and suPAR <12 ng/ml with mortality 5.5%; ii) APACHE II < 17 and suPAR ≥12 ng/ml with mortality 17.4%; iii) APACHE II ≥ 17 and suPAR <12 ng/ml with mortality 37.4%; and iv) APACHE II ≥17 and suPAR ≥12 ng/ml with mortality 51.7%. This prediction rule was confirmed by the Swedish cohort. Conclusions: A novel prediction rule with four levels of risk in sepsis based on APACHE II score and serum suPAR is proposed. Prognostication by this rule is confirmed by an independent cohort.

1 February 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
NVNikos Viazis
Nikos Viazis
KAkonstantinos argyriou
konstantinos argyriou
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
PAPeriklis Apostolopoulos
Periklis Apostolopoulos
GMGerassimos J Mantzaris
Gerassimos J Mantzaris
Aim: To establish whether the addition of probiotics to a globally accepted Helicobacter pylori (H. pylori)-eradication scheme may reduce the rates of side effects and increase the eradication rates. Methods. Prospective, randomized, placebo-controlled trial of patients receiving eradication therapy for H. pylori in the eight participating centers. All patients received a 10-day proton pump inhibitor containing non-bismuth quadruple therapeutic regimen for H. pylori eradication (omeprazole 20 mg, amoxycillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg all twice daily orally) and were randomized to receive either probiotics (group A) or placebo (group B). The probiotic used combined four probiotic strains, i.e., Lactobacillus Acidophilus, Lactiplantibacillus plantarum, Bifidobacterium lactis, and Saccharomyces boulardii. Results. Data were analyzed for 329 patients in group A and 335 patients in group B. Fifty six (17.0%) patients in group A and 170 (50.7%) patients in group B reported the occurrence of an H. pylori treatment-associated new symptom or the aggravation of a pre-existing symptom of any severity (p < 0.00001). H. pylori was successfully eradicated in 303 patients in group A (92.0%) and 291 patients in group B (86.8%), (p = 0.028). Conclusion: Adding probiotics to the 10-day concomitant non-bismuth quadruple H. pylori eradication regimen increases the eradication rate and decreases side effects.